GSK3862995 vs tozorakimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanism: IL-33 · full Chronic Obstructive Pulmonary Disease pipeline

GSK3862995

Developed by GlaxoSmithKline

Phase 1 in Chronic Obstructive Pulmonary Diseasemonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT06154837 (registry estimate)

No aligned efficacy figure on record for this race.

tozorakimab

Developed by AstraZeneca

Phase 3 in Chronic Obstructive Pulmonary Diseasemonoclonal antibody
Partial signal

NCT06040086 · Phase 3 · completed

The study was randomized, quadruple-blind, and placebo-controlled, with 1,454 participants, and evaluated a clinical exacerbation outcome. However, no primary endpoint results or statistical comparison are available, so the treatment effect cannot yet be judged.

Next expected readout: December 2028 · NCT07566195 (registry estimate)

Reported efficacy

Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers. (Over 52 weeks): Primary endpoint met: statistically significant reduction in the annualised rate of moderate-to-severe COPD exacerbations in former smokers and the overall population (MIRANDA, AstraZeneca, 2026-04-20). (met)

Result source: NCT06040086

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGSK3862995tozorakimab
Moderate or severe exacerbations, annualised rate—Not reported—Not posted · NCT05158387
Trough FEV1, change—Not reported—Not posted · NCT05158387
SGRQ total, change—Not reported-9.2 vs -8.3−0.9 vs placebowk 12 · n 62NCT04631016
TDI focal score—Not reported—Not posted · NCT05158387

Moderate or severe exacerbations, annualised rate

GSK3862995
—Not reported
tozorakimab
—Not posted · NCT05158387

Trough FEV1, change

GSK3862995
—Not reported
tozorakimab
—Not posted · NCT05158387

SGRQ total, change

GSK3862995
—Not reported
tozorakimab
-9.2 vs -8.3−0.9 vs placebowk 12 · n 62NCT04631016

TDI focal score

GSK3862995
—Not reported
tozorakimab
—Not posted · NCT05158387
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

GSK3862995: no structured comparison results are available for Chronic Obstructive Pulmonary Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. GSK3862995: 0 of 4 rows · tozorakimab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metrictozorakimab
Dropout rate
15.9%a
NCT04631016 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
4.3%a
NCT04631016 · Phase 2 · registry result, not featured evidence
Serious AEs
20.9%a
NCT04631016 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
chronic obstructive pulmonary disease 38.8% (placebo 39.7%)
covid-19 20.9% (placebo 20.6%)
injection site erythema 14.9% (placebo 0%)
NCT04631016 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

tozorakimab

FEV1 0.019 vs -0.005 placebo L @ 12wk
absolute change · L
NCT04631016 · Phase 2 · registry result, not featured evidence
Exacerbation Occurrence 41.8% (n=67) vs 52.9% (n=68) placebo @ 28wk
event count · % of participants
NCT04631016 · Phase 2 · registry result, not featured evidence · converted to % from 28 Participants as posted
E-RS Total -6.09 vs -6.06 placebo score @ 12wk
absolute change · score
NCT04631016 · Phase 2 · registry result, not featured evidence
BCSS -2.18 vs -2.18 placebo score @ 12wk
absolute change · score
NCT04631016 · Phase 2 · registry result, not featured evidence
Cough VAS -17.21 vs -17.7 placebo mm @ 12wk
absolute change · mm
NCT04631016 · Phase 2 · registry result, not featured evidence
SGRQ Total -9.177 vs -8.273 placebo score @ 12wk
absolute change · score
NCT04631016 · Phase 2 · registry result, not featured evidence
SGRQ 61.3% (n=62) vs 61.5% (n=65) placebo @ 12wk
responder rate · % of participants
NCT04631016 · Phase 2 · registry result, not featured evidence
Cough Frequency 0.89 vs 0.83 placebo ratio @ 12wk
ratio to baseline · ratio
Daily cough frequency
NCT04631016 · Phase 2 · registry result, not featured evidence
FEV1 0.031 vs 0.006 placebo L @ 28wk
absolute change · L
Pre-BD FEV1
NCT04631016 · Phase 2 · registry result, not featured evidence
Post-BD FEV1 Change -0.039 vs -0.018 placebo L @ 28wk
absolute change · L
Post-BD FEV1
NCT04631016 · Phase 2 · registry result, not featured evidence
FEV1 -0.015 vs -0.068 placebo L @ 28wk
absolute change · L
Pre-BD FEV1 Week 28
NCT04631016 · Phase 2 · registry result, not featured evidence
Post-BD FEV1 Change 0.074 vs -0.053 placebo L @ 28wk
absolute change · L
Post-BD FEV1 Week 28
NCT04631016 · Phase 2 · registry result, not featured evidence

+ 2 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GSK3862995's landscape · tozorakimab's landscape